system suitability tests (HPLC/GC): meaning, evidence and controls
A practical guide to chromatographic readiness, method-specific acceptance criteria, traceable evidence and defensible handling of failed or interrupted sequences.

On this page · 11 sections
- 1What system suitability tests establish in HPLC and GC
- 2Compare SST with validation, calibration, sampling, identity and release
- 3Map US supplement rules, US drug rules and guidance
- 4Choose method-specific criteria and a justified SST check schedule
- 5Run readiness checks within a controlled chromatographic sequence
- 6Keep the evidence behind every system suitability decision
- 7Worked HPLC case: resolving a supplement assay critical pair
- 8Worked GC case: stable ratios with declining absolute signals
- 9Worked sequence case: isolating results after a failed check
- 10Recover exceptions and reconcile chromatographic data across laboratory systems
- 11Review the sequence and maintain the control strategy
How does System Suitability Tests (HPLC/GC) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What system suitability tests establish in HPLC and GC
system suitability tests (HPLC/GC) are method-specific readiness checks for the chromatographic measurement system and associated analytical operations used for an intended analysis. This definition follows the terminology of the ICH Q2(R2) glossary entry for system suitability test, used here as a technical reference rather than a supplement-specific legal requirement.
In laboratory practice, the relevant system extends beyond the instrument: it includes the column, detector, analytical conditions, reference preparations, and acquisition and processing settings. The selected checks challenge particular operations within that system, such as injection repeatability, separation or response measurement. The choice of reference standard or reference material therefore matters: the preparation needs to challenge the performance characteristic being assessed, not merely produce a detectable peak.
A passing observation describes performance at the point tested and under the conditions used. Evidence of continuing performance comes from appropriately placed checks across the analytical work, interpreted alongside sequence events and changes in chromatographic behaviour. An initial pass alone does not demonstrate that later injections remained unaffected by drift or deterioration.
For supplement chromatography, botanical complexity, differences in constituent concentrations and potential interference make the choice of challenge especially important. A clean reference preparation may exercise injection consistency without challenging separation from a nearby botanical component. SST is therefore one part of using a scientifically valid method, with its decision boundary tied to what the selected checks actually test.
02Compare SST with validation, calibration, sampling, identity and release
In laboratory practice, these controls answer different questions. A passing SST does not establish a validated method, correct ingredient identity, a representative sample or authorization to release product.
| Control | Question answered | Evidence examined | Conclusion not established |
|---|---|---|---|
| System suitability | Does the system meet method-specific checks? | Critical-pair separation; replicate standard responses | Validity of every sample result |
| Analytical-procedure validation | Is the procedure fit for its intended use? | Selectivity, accuracy, precision and range studies | Readiness of today's system |
| Instrument qualification or calibration | Is equipment suitable or measurement performance acceptable? | Qualification tests; calibration comparisons | Performance of the complete analytical procedure |
| Sample suitability and preparation | Is this preparation appropriate for analysis? | Condition, extraction recovery, dilution and stability records | Representativeness of the lot |
| Representative sampling | Does the sample adequately represent the material? | Sampling plan; locations and increments | Correct analytical identification |
| Ingredient identity | Is the intended ingredient present? | Reference comparison; discrimination from plausible interferents | Acceptability of all product attributes |
| Authorized product release | Is the product approved for disposition? | Authorized review of specifications, batch records and exceptions | Readiness of a subsequent analytical sequence |
Repeated injections from one standard vial assess injection-response repeatability. They do not measure variability introduced by sampling, extraction, dilution or independent sample preparation. Independent preparations challenge only the extraction, dilution and other operations actually repeated; they do not automatically repeat material sampling. Assessing lot-sampling variability or representativeness requires a separately designed sampling comparison.
A retention-time match can support identity, but an interferent may coelute with the target. Acceptable system performance alone cannot distinguish them. Where interference is plausible, identity assessment typically needs demonstrated selectivity or a complementary discriminating test.
03Map US supplement rules, US drug rules and guidance
Start with the product’s regulatory category, not the chromatography platform. A practical regulatory map keeps supplement laboratory procedures, drug laboratory controls and analytical guidance in separate lanes. Using the same instrument does not make their applicability interchangeable.
| Jurisdiction and product | Authority | Relevant laboratory question | Applicability boundary |
|---|---|---|---|
| US dietary supplements | Binding regulation: 21 CFR 111.320 | What laboratory scope applies to this supplement procedure? | Consult the current provision within the supplement CGMP framework. Keep this assessment separate from drug provisions. |
| US drugs | Binding regulation: 21 CFR 211.160 | Which laboratory controls apply to the proposed testing operation? | Check scope within the drug CGMP framework, rather than importing drug provisions into supplement practice. |
| US drugs | Binding regulation: 21 CFR 211.194 | How will the laboratory record connect the sample, method, calculations and reported result? | Use the record-review navigation below; check each provision’s current text for applicable content. |
| US human-drug analytical validation | FDA guidance: ICH Q2(R2), sections 2.1 and 3.4 | Where should validation-study and robustness questions be assessed? | Consult those sections for scope; do not treat analytical guidance as a blanket supplement mandate. |
For US dietary supplements, 21 CFR 111.320(a)–(b) requires verification that laboratory examination and testing methodologies are appropriate for their intended use, and identification and use of an appropriate scientifically valid method for each established specification requiring examination or testing. This is supplement-method suitability, not an automatic transfer of drug laboratory rules or a universal SST numerical limit.
For laboratory review, examine the sample description as a practical identification check. For US drugs, 21 CFR 211.194(a)(2) requires a statement of each method used; (a)(5) requires a record of calculations including units, conversion and equivalency factors; (a)(6) requires test results and their comparison with established standards. Those laboratory records are broader than an SST report.
For US drugs, 21 CFR 211.194(a)(2) requires verification of testing-method suitability under actual conditions of use. A passing individual SST is not itself that demonstration. Under 21 CFR 211.160(a), required laboratory controls and changes are drafted by the appropriate unit and reviewed and approved by the quality control unit; deviations are recorded and justified.
For US human-drug analytical validation, ICH Q2(R2) describes FDA guidance as recommendations unless specific regulatory or statutory requirements are cited. Operationally, maintain separate references for legal obligations, guidance-based validation decisions and method-specific SST criteria. This map attributes no numerical acceptance limits, injection counts, check intervals or adjustment permissions to USP chromatography provisions.
04Choose method-specific criteria and a justified SST check schedule
As laboratory practice, select SST criteria around failures that could compromise the intended result, not a generic instrument checklist. Method development, robustness studies, intended use and operating experience can inform each limit and its documented rationale. The matrix below suggests ownership; assign actual approval responsibilities through the laboratory’s controlled procedure.
| Analytical risk | Candidate measurement | Calculation convention | Acceptance-criterion owner | Check location |
|---|---|---|---|---|
| Interference between critical peaks | Critical-pair resolution | Named pair; concentration; integration rules; baseline or half-height widths | Method owner | Initial challenge mixture; justified later checks |
| Variable injection or response | Peak-area or response-ratio repeatability | Defined replicates, statistic and internal-standard ratio orientation | Method owner | Initial replicate set; scheduled repeat sets |
| Distortion affecting integration | Peak asymmetry or tailing | Named peak, formula and measurement height | Method owner | Initial and scheduled standards |
| Loss of column performance | Efficiency | Named peak; plate calculation and width convention | Method owner | Initial check; after relevant column intervention |
| Insufficient low-level response | Sensitivity at relevant concentration | Signal definition, noise window and algorithm | Method owner | Initial low-level check; justified later checks |
An unexplained resolution value is weak evidence: name the challenged analyte/interferent pair, applicable concentrations, integration convention and peak-width convention. Different conventions can yield different values. Apply comparable specificity to other calculations, including software settings. During analytical method transfer, align these definitions rather than comparing pass flags alone.
Keep blank contamination, carryover and calibration checks separately identifiable. A blank challenges background contamination; a blank after a high-response injection challenges carryover; calibration checks challenge the response-to-concentration relationship. Their placement may overlap SST, but their questions and acceptance decisions differ.
Use the approved procedure’s justified schedule: initial checks before sample measurements, intermediate checks where long sequences risk drift, and closing checks where end-of-sequence evidence is needed. Define which interventions trigger renewed checks—for example, column replacement or inlet maintenance—and which measurements address the resulting risk. Schedule by analytical exposure and stability knowledge, rather than assuming a blanket daily SST rule.
Keep predefined acceptance criteria distinct from diagnostic observations and historical warning trends. A deteriorating but passing result can prompt out-of-trend handling; it does not itself redefine the limit. Do not change a criterion to accommodate an inconvenient result. Evaluate proposed revisions separately, with scientific rationale and controlled approval before future use.
05Run readiness checks within a controlled chromatographic sequence
In routine HPLC and GC practice, sequence control connects preparation, acquisition and evaluation. The following workflow is a practical operating model, not a universal regulatory sequence prescription.
- Establish the assignment. Start with the intended analytical question, applicable method version and authorized sequence design. At the sample login handoff, connect the requested test to the sample identifier and preparation instructions. The analyst checks relevant instrument status, column identity and recorded restrictions before preparing the run.
- Prepare and establish operating conditions. Identify reference materials and their lots; link weighing, dilution and preparation records to the solutions actually injected. Record mobile-phase preparation or carrier-gas conditions, as applicable. Follow the approved procedure for equilibration and coordinate sample-preparation timing with the planned acquisition window and established preparation stability.
- Assign injection roles. Distinguish blanks for background or carryover assessment, suitability preparations for system-performance evaluation, calibration standards for response modelling, check standards for continuing performance observations and samples for reportable measurements. Where a preparation serves multiple purposes, document each role and its applicable evaluation rather than treating the labels as interchangeable.
- Acquire and evaluate. The analyst records preparation and acquisition activity; the designated technical evaluator assesses suitability before relying on sample results. Evaluate continuing checks at the locations defined in the sequence design. Explicitly associate sample injections with the relevant performance observations, including checks after those samples where the procedure uses them.
- Hand off for review or investigation. Route the sequence, evaluations and unresolved observations to the authorized reviewer. If a check fails or acquisition is interrupted, identify the potentially affected injections and assign investigation ownership before deciding their disposition. Exception-based review can focus attention on flagged events without replacing the underlying technical evaluation. The recovery section below addresses investigation, corrective action and any proposed repeat analysis.
- Select procedureIdentify intended use, approved method version, criteria and check schedule.
- Prepare systemConfirm instrument state, column, preparations and reference-material traceability.
- Acquire ChecksRun the defined blanks, suitability preparations and associated controls.
- Evaluate criteriaCalculate specified metrics and retain chromatograms, settings and evaluation outcomes.
- Monitor sequenceAssociate sample injections with applicable initial and continuing performance checks.
- Resolve exceptionsHold affected results while investigating failures, interruptions or unexplained changes.
- Review dispositionRecord the human decision on analytical usability and subsequent routing.
06Keep the evidence behind every system suitability decision
A reconstructable SST decision connects the approved method version to the sequence, individual injections, criterion evaluations and reviewer decisions. These are proposed record-design fields, not a statement of legal record requirements; the regulatory map addresses those separately.
- Method and sequence: link the method identifier and version, acquisition settings, sequence identifier, instrument identifier and column identifier. Preserve the planned injection order alongside the executed order so interruptions and additions remain visible.
- Preparations and injections: assign each injection a persistent identifier and role, such as blank, suitability solution, reference standard or sample. Connect it to preparation identifiers, reference-material lot and certificate records, acquisition timestamps and retrievable raw-data locations.
- Criterion evaluations: retain the input observations, their measurement units, equation or calculation version, applicable criterion, observed value and evaluation outcome for each metric. Identify the injections included in replicate calculations and document exclusions rather than silently changing the calculation population.
- Review decisions: link the reviewer identity, review timestamp, decision, rationale and any unresolved exception to the particular evaluation reviewed. Identify which sequence results that decision covers, rather than leaving its scope implicit.
Attach chromatograms, integration events and processing changes to their original injection identifiers. Keep acquisition timestamps distinct from later processing and evaluation timestamps. Preserve relevant processing-method versions, integration parameters, change reasons and resulting evaluations so a reviewer can distinguish newly acquired evidence from a different interpretation of existing data.
Keep failed checks, interrupted sequences and repeat work in the same linked history. A later passing evaluation should not hide the earlier failure or replace its evidence. Apply requirements traceability to connect criteria with their approved basis, and use a data integrity risk assessment to identify vulnerable links, such as exported reports detached from source injections.
Method Version
Defines intended checks.
- method_version_id
- intended_use
- sst_criteria
- check_schedule
- approved_by
Analytical Sequence
Groups acquisition activity.
- sequence_id
- method_version_id
- instrument_id
- column_id
- started_at
Injection Record
Locates original observations.
- injection_id
- sequence_id
- preparation_id
- injection_role
- acquired_at
- raw_data_uri
Criterion Evaluation
Preserves calculation context.
- evaluation_id
- injection_ids
- criterion_id
- measured_value
- measurement_unit
- processing_version_id
- evaluation_status
Review decision
Records scope and disposition.
- review_id
- sequence_id
- affected_injection_ids
- investigation_id
- reviewer_id
- analytical_disposition
- reviewed_at
07Worked HPLC case: resolving a supplement assay critical pair
Assume an HPLC supplement assay has a designated critical pair: the analyte and a neighbouring component whose separation matters to quantitation. Both peaks use matching baseline-width conventions and initially have equal baseline widths. Let d be their positive retention-time separation in minutes, w each peak’s positive baseline width in minutes, and c the approved method’s positive, dimensionless resolution criterion. This illustrative calculation uses no pharmacopoeial acceptance threshold.
Using baseline widths, resolution is twice the retention-time separation divided by the sum of the peak widths. Here, R = 2d/(w + w) = d/w. Its units are minutes divided by minutes, so R is dimensionless and can be compared directly with c. Widths measured at another peak height cannot simply be substituted into this calculation; the measurement convention is part of the calculation’s meaning.
Now assume both peaks broaden by the same dimensionless factor k > 1 while d stays constant. Each width becomes k·w minutes, giving R_broadened = 2d/(k·w + k·w) = d/(k·w). Choose the case ordering c·w < d < c·k·w. Dividing the left inequality by positive w gives d/w > c: the original condition exceeds the criterion. Dividing the right inequality by positive k·w gives d/(k·w) < c: the broadened condition fails. No numerical cutoff is needed to establish the reversal.
The practical response is to examine column condition, mobile-phase preparation, flow, temperature and integration consistency against the approved procedure. Compare chromatograms and baseline placement before attributing the change to the column alone. Document the diagnostic checks in laboratory standard work. Acceptable area repeatability does not substitute for the failed separation criterion: repeatable integrated areas can coexist with inadequate separation. Any corrective adjustment and subsequent suitability assessment should follow the controlled procedure, not a retrospective relaxation of c.
08Worked GC case: stable ratios with declining absolute signals
Assume a GC-FID procedure using a fixed internal-standard concentration, correctly prepared comparison solutions and detector areas expressed in pA·s for this example. Assume linear detector response and consistent integration. Let A be the positive analyte peak area and I the positive internal-standard peak area. The response ratio is R = A/I; its units cancel, so R is dimensionless.
Now apply the same positive response-loss factor k, smaller than unity, to both signals. The later areas are k·A and k·I. Calculating the later ratio gives Rlater = (k·A)/(k·I) = A/I = R. Both absolute areas have declined, but the ratio is exactly unchanged. This idealised cancellation assumes equal proportional losses; actual observations may depart from that assumption.
Assess these observations separately against checks actually defined in the approved procedure. A ratio-based check may remain acceptable while an applicable absolute-response or sensitivity check fails. Conversely, an area decline is not automatically an SST failure where no relevant criterion is breached. Do not invent an acceptance limit after seeing the chromatogram. Where a defined criterion fails, route the event through the applicable out-of-specification handling process.
Diagnostic hypotheses include injection-volume variation, inlet problems and detector-response changes. The ratio alone cannot distinguish them or establish a root cause. A defensible investigation commonly brings together original detector signals, peak integrations and any integration changes, solution-preparation history, injection and operating events, and results against the applicable sensitivity or response controls. Compare the timing of signal changes with those events before attributing the loss to a particular component.
09Worked sequence case: isolating results after a failed check
Illustrative supplement HPLC case: assume the approved procedure defines bracketing, continuing-check criteria, preparation stability and investigation rules. Injection order is: passing initial SST → sample block A → passing bracket → sample block B → failed continuing check. A logged pump-pressure disturbance occurs during block B. Its event-log timestamp precedes the failed-check acquisition timestamp: the disturbance is an observation, while the failed check marks detection, not necessarily onset.
Build an affected-result map in the investigation record, linked to the sequence in the laboratory information management system:
| Result group | Evidence questions |
|---|---|
| Block A | Do both passing checks cover the relevant failure mode? Do chromatograms or instrument trends suggest an earlier problem? |
| Block B before disturbance | Does the passing bracket support these injections? Could deterioration have started before the logged event? |
| Block B after disturbance | Which injections overlap abnormal pressure or altered chromatography? What does the failed continuing check leave unresolved? |
For each group, record injection identifiers, applicable checks, instrument observations, preparation age and storage against established stability, and the procedure’s investigation rule. Keep unresolved results pending assessment; neither the earlier pass nor the later failure settles every result’s status.
- Reinjecting a stable existing preparation examines injection or system performance without repeating preparation.
- Preparing a fresh test solution examines preparation-related effects or replaces a solution outside established stability.
- Repeat sampling examines whether the original sample adequately represents the material; it does not diagnose a pump disturbance.
Document analytical disposition by result group, retaining original data and rationale. Before relying on subsequent results, document corrective action, restored method-specific suitability and preparation stability. Apply the downstream decision boundaries in the earlier comparison table.
10Recover exceptions and reconcile chromatographic data across laboratory systems
A practical exception workflow places potentially affected results in a held or unresolved state. Preserve original acquisitions, processing histories and failed evaluations; investigate cause and scope through the laboratory’s deviation process. Recovery follows approved corrective action, appropriate repeat checks and documented review—not replacement of the failed history.
Use this exception-control table as a planning aid. Recovery paths depend on the approved procedure and investigation findings, not analyst discretion alone.
| Failure mode | Immediate containment | Diagnostic evidence | Permitted recovery path | Reviewer decision |
|---|---|---|---|---|
| Unresolved coelution | Hold affected determinations | Critical-pair traces; column history | Restore separation; repeat suitability | Is selectivity demonstrated? |
| Drifting response | Hold implicated interval | Response trends; preparation ages | Correct cause; repeat justified checks | Which results remain supportable? |
| Unstable integration | Hold reported values | Raw traces; processing history | Justified controlled reprocessing | Are boundaries defensible? |
| Incorrect method version | Hold sequence | Executed versus approved settings | Assess differences; authorize reanalysis if needed | Was intended performance established? |
| Preparation instability | Hold affected preparations | Preparation times; storage; stability evidence | Fresh preparations and appropriate checks | Which preparations were affected? |
| Instrument interruption | Hold interrupted interval | Event logs; acquisition completeness | Restore operation; assess restart checks | Which acquisitions are usable? |
| Repeated injections pursued only to obtain a pass | Stop discretionary reinjection | Full injection history; analyst rationale | Investigate; approve a justified repeat plan | Is selective reporting excluded? |
At the chromatographic data system–laboratory information management system handoff, reconcile stable sample, preparation, sequence and injection identifiers. Carry units, acquisition-method and processing versions, timestamps with time-zone context, and exported evaluation status alongside values. A numerical result without its held status can be mistaken for an accepted result.
Link the quality-management investigation to affected results and corrections. Compare transfer acknowledgments with source records; detect duplicate transfers without silently overwriting earlier records. If a chromatogram disagrees with a summary report, check injection identity, processing version, units and report-generation timing before choosing either representation. Retain superseded exports with their correction history and reconcile receiving records before downstream use.
The final analytical disposition is a documented human approval identifying accepted, superseded or unresolved results and the supporting rationale.
11Review the sequence and maintain the control strategy
Use this practice-based checklist to assign evidence questions and unresolved actions. Record the responsible person and disposition beside each open item; a checked box alone does not explain the decision.
Method owner: is the control strategy explicit?
Inspect the approved procedure and supporting development records. Do they connect intended use to justified metrics, calculation conventions, acceptance criteria and check placement? Are intervention triggers defined, including when checks are repeated after adjustments? Is responsibility for proposing and approving changes assigned? If unresolved, refer the gap to the method owner before using an improvised criterion or schedule.
Analyst: can the planned sequence be traced?
Compare procedure, acquisition and processing versions with the sequence setup. Inspect preparation records, material identifiers, dilution calculations, vial assignments and injection roles. Do acquisition settings match the method? Are all relevant injections preserved, including aborted runs and troubleshooting injections? Resolve mismatches before proceeding; if acquisition has begun, preserve existing data and document the discrepancy.
Reviewer: does the evidence support the decision?
Reconstruct calculations from recorded inputs and inspect chromatographic plausibility rather than relying on summary flags. Examine integration changes and the audit trail, failed checks, affected-result assessments and supporting rationale. Does the decision record identify results retained, excluded or awaiting investigation, with reasons and review attribution? Return unexplained changes or incomplete assessments for resolution before accepting the analytical conclusion.
Laboratory manager: what needs follow-up?
Review trends stratified by method version, instrument, column and preparation conditions. Could pooled data conceal a local deterioration? Treat a warning trend through out-of-trend handling; distinguish it from failure against an approved acceptance criterion. Assign unresolved signals to a named investigator. For proposed changes, use change control to ask what performance evidence needs reassessment, who approves the assessment, and what follow-up demonstrates that the revised controls remain appropriate for intended use.
Frequently asked questions
Q.What should a contract laboratory report so a supplement manufacturer can review an SST pass?+
A useful review package typically identifies the analytical procedure and revision, instrument, column, standard preparation, injection sequence, acceptance criteria and actual results—not just a pass flag. Include chromatograms, integration details, calculation settings, relevant sequence interruptions and explanations of excluded injections. Identify which sample injections the suitability assessment covers and who reviewed it. Agree on access to underlying electronic records when establishing the laboratory arrangement. Traceability of the reference standard helps the manufacturer assess whether the check material was appropriate.
Q.How should SST scheduling be handled across overnight or unattended sequences?+
Typically, the approved procedure defines checks around the analytical sequence using evidence about system drift, solution stability and the consequences of an undetected failure. Overnight operation alone is not a scientific basis for choosing the interval. Plan check placement, interruption responses and the treatment of samples between acceptable and failed checks before starting. Include autosampler conditions and reagent stability in the assessment. A passing startup check does not establish that performance remained acceptable throughout an unattended run.
Q.What should be reassessed after changing an instrument, column lot or analytical procedure?+
Use change control to identify which measurement characteristics the change could affect. Instrument changes may alter gradient delivery, detector response or injection behavior; column-lot changes may alter selectivity even when nominal specifications match. Procedure changes may affect extraction, calibration or integration. Typically, the assessment compares relevant performance against the established method basis and determines whether suitability testing, targeted experiments, transfer work or broader validation work is appropriate. An unchanged SST pass alone may not address the changed feature.
Q.When can standard reinjection help distinguish a vial problem from instrument instability?+
Reinjection is useful when it tests a documented hypothesis rather than searches for a passing result. Compare the suspect vial with a freshly filled vial from the same solution under otherwise unchanged conditions. If necessary, compare an independently prepared standard to separate solution preparation from vial handling. Examine injection order, pressure, retention and response together. Document the investigation through attributable recording, retaining the original injections. Recovery after reinjection is an observation, not proof that the original problem was harmless.
Q.How can historical SST failures be trended without mixing incompatible method versions?+
Typically, trend records retain the method revision, criterion definition, calculation convention, standard concentration, column configuration and processing version alongside each result. Group results only where those features support a meaningful comparison; mark changes rather than silently pooling them. Track failure modes and investigation outcomes as well as pass rates. Define the denominator consistently, including how aborted sequences and repeat attempts are counted. Out-of-trend handling can then distinguish gradual deterioration from a discontinuity introduced by a revised criterion.
Q.What should be investigated when a botanical sample shows interference but standard checks remain acceptable?+
Investigate sample-specific selectivity and preparation effects. A clean standard does not reproduce a botanical extract’s coextractives, degradation products or extraction artifacts. Compare appropriate blanks, unspiked and spiked extracts, and changes in peak shape or spectral information where available. Consider whether dilution, extraction conditions or another analytical approach can test the suspected interference without concealing it. Connect the investigation to the method’s scientific validity for that matrix. Treat ingredient identity and reportable analyte concentration as separate questions requiring appropriate evidence.
Q.Who should resolve a mismatch between the chromatogram and the exported SST evaluation?+
Typically, the analyst and laboratory reviewer reconcile the chromatographic record with the reported calculation; a chromatography-system administrator or informatics specialist helps investigate configuration and export behavior. Quality personnel assess the effect on reviewed or distributed results. Compare injection identifiers, processing revisions, peak assignments, units, rounding and report formulas, using the audit trail where available. Preserve both conflicting records and document the resolution. Do not settle the discrepancy by editing the exported pass flag without establishing which result is technically correct.
Q.How can carryover be investigated when peak-area repeatability remains acceptable?+
Repeatability measures consistency; a consistent residual contribution can remain hidden within apparently repeatable areas. Typically, carryover investigations place suitable blanks after a high-response standard or sample and examine whether residual analyte response decays with subsequent injections. Compare blanks before the challenge to distinguish background contamination from sequence-dependent residue. Investigate wash solvents, needle and seat surfaces, injection pathways and, for GC, relevant inlet components. Record the work through a deviation investigation, assessing the potential effect on low-response samples that followed.
Primary sources
Want to see how System Suitability Tests (HPLC/GC) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
